Generated by AI
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its lead program is telitacicept, a dual-target fusion protein designed to regulate abnormal B-cell activity that drives autoantibody-mediated conditions. The company’s current development and commercialization efforts center on autoimmune indications such as generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s disease, and IgA nephropathy. Vor Biopharma works on advancing this therapy through clinical development and broader market access, positioning its platform within the specialized immunology and biopharmaceutical segments. Headquartered in Cambridge, Massachusetts, Vor Biopharma plays a role in the market by addressing serious chronic diseases with targeted biologic treatment approaches.
Website500 Boylston Street
Boston, MA, 02116
United States
The latest articles about VOR.
Vor Biopharma has seen a sharp swing in fortunes over the past few years, and the stock’s long slide now sits against a much stronger year to date. With that backdrop, the key issue for investors is whether the current share price is in line with what Vor Biopharma’s earnings can reasonably support. The share price has fallen 94.4% over the past 5 years, which puts a lot of weight on the question of whether today’s valuation still lines up with the business’s earnings power. Recent updates...
Summary of Feb 23's posts. Generated by AI.
Summary of Dec 30's posts. Generated by AI.
Summary of Jun 26's posts. Generated by AI.
Summary of Dec 30's posts. Generated by AI.
Investors talking about VOR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.